Thermo Fisher takes over operation of $1bn CSL facility

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Natee Meepian)
(Image: Getty/Natee Meepian)

Related tags: Thermo fisher scientific, CSL, Switzerland

A strategic partnership is announced that sees Thermo Fisher run the Swiss site and manufacture CSL’s products.

Originally, CSL Behring had decided to build the Lengnau production facility to manufacture its own recombinant coagulating factors, among other products. Work on the site began in 2014 and the initial estimate of the cost was set at CHF 1bn (€937m).

Yesterday, it was announced that Thermo Fisher Scientific had agreed a long-term lease agreement with CSL that would see the contract development and manufacturing organization (CDMO) takeover operations at the site.

The deal has been reached despite the site not yet being fully operational – according to the companies, the construction will be completed in mid-2021 and the original projections for the facility becoming operational was set between 2022 and 2023.

In terms of scale, the facility will cover 466,000-square-feet, with space for expansion, and house approximately 300 staff members.

As part of the deal, Thermo Fisher will produce CSL’s hemophilia products before expanding to utilize the site to add further biopharma customers.

The site is equipped with single-use and stainless-steel equipment to be able to produce treatments at large-scale.

As to why CSL had decided to lease the facility, Paul McKenzie, chief operating officer at CSL, explained, “As part of the CSL board of directors' strategic review, we are in the process of transforming our end-to-end supply chain with a view to ensuring the company's global manufacturing network is operating at a best-in-class level.”

He continued to say that this would see the biotech balance internal investment with access to ‘capabilities and capacities’ that are available through working with a CDMO, such as Thermo Fisher.

For the CDMO, the facility adds an additional location to its European network, as well as continues its strategic push to invest more funds into the biologics side of its business – which saw it commit to invest $475m in biopharma operations during 2020​.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us


View more